TickerKhojComparison · NSE · data 2026-11-02
Alivus Life Sciences Ltd vs OneSource Specialty Pharma Limited
In plain words
Size: OneSource Specialty Pharma Limited is about 1 times the market value of Alivus Life Sciences Ltd.
Return on equity: Alivus Life Sciences Ltd 18.4% vs OneSource Specialty Pharma Limited -1.3%.
Debt to equity: OneSource Specialty Pharma Limited 0.26 vs Alivus Life Sciences Ltd 0.02.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ALIVUS | ONESOURCE | |
|---|---|---|
| Price | ₹1,447.5 | ₹1,583.1 |
| Market cap | ₹17,284 cr | ₹17,926 cr |
| P/E | 26.6 | — |
| P/B | 4.9 | 3.1 |
| ROE | 18.4% | -1.3% |
| ROCE | 22.4% | -0.1% |
| Debt / equity | 0.02 | 0.26 |
| Operating margin | 31.3% | 6.4% |
| Dividend yield | 0.36% | 0.00% |
| Sales growth, 3 years (yearly) | 5.7% | 232.4% |
| Profit growth, 3 years (yearly) | 6.5% | — |
| 1-year return | 59.4% | -14.4% |
| Revenue, last 12 months | ₹2,684 cr | ₹1,684 cr |
| Net profit, last 12 months | ₹670 cr | ₹-2 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹197 cr | ₹25 cr |
| Quarter profit vs a year earlier | +51.3% | — |
| Promoter holding | 74.85% | 30.47% |
| Health check | Strong (8.5/10) | Weak (3.5/10) |
Common questions
Which earns a higher return on equity?
Alivus Life Sciences Ltd (18.4% against -1.3%).
Which carries more debt?
OneSource Specialty Pharma Limited has the higher debt-to-equity ratio (0.26 against 0.02).